Molecular Imaging in NHP Models: Biodistribution, Target Engagement & Translational Drug Development

Molecular Imaging in NHP Models for Translational Drug Development How can molecular imaging help connect drug exposure, target engagement, and biological response in non-human primate (NHP) studies? In this webinar, Prisys Biotechnologies discusses how molecular imaging can complement conventional NHP study endpoints and provide longitudinal, quantitative in vivo evidence to support translational drug development. The webinar covers: • The role of NHP models in generating translational evidence • Multimodal imaging approaches, including PET/CT, SPECT/CT, MRI, CT, and DSA • Imaging-guided CNS and organ-targeted drug delivery • Longitudinal assessment of drug distribution and biological response • AI-assisted behavioral and safety monitoring in NHP studies • Why molecular imaging matters in translational drug development • Molecular imaging applications in biodistribution, PK/PD, target engagement, toxicology and safety, and dosimetry • Integration of molecular imaging with NHP disease models and complementary biological endpoints The discussion highlights how image-derived in vivo endpoints can be integrated with pharmacology, PK/PD, biomarkers, and functional assessments to build a more comprehensive translational dataset. For more information about Prisys Biotechnologies and our NHP translational research capabilities: Contact: bd@prisysbiotech.com #MolecularImaging #NHPModels #TranslationalDrugDevelopment #NonHumanPrimates #DrugDevelopment #Biodistribution #TargetEngagement #PKPD